These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 28797188

  • 1. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.
    Armstrong A, Puig L, Langley R, Tsai TF, Song M, Wasfi Y, Jiang J, Li S, Han C.
    J Dermatolog Treat; 2019 Feb; 30(1):27-34. PubMed ID: 28797188
    [Abstract] [Full Text] [Related]

  • 2. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [Abstract] [Full Text] [Related]

  • 3. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
    Reich A, Pinter A, Maul JT, Vender RB, Torres T, Brnabic A, Haustrup N, Reed C, Schuster C, Riedl E.
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
    [Abstract] [Full Text] [Related]

  • 4. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis.
    Proietti I, Bernardini N, Skroza N, Mambrin A, Tolino E, Marchesiello A, Marraffa F, Rossi G, Volpe S, Potenza C.
    Rev Recent Clin Trials; 2022 Jun 23. PubMed ID: 35747967
    [Abstract] [Full Text] [Related]

  • 8. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
    Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassilis C, Nelson LM, McLeod LD, Mordin M, Gottlieb AB, Elewski BE, Lebwohl M.
    Int J Dermatol; 2016 Mar 23; 55(3):e147-55. PubMed ID: 26518255
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 23; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 11. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.
    J Eur Acad Dermatol Venereol; 2018 Aug 23; 32(8):1305-1313. PubMed ID: 29512200
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB.
    Am J Clin Dermatol; 2020 Dec 23; 21(6):881-890. PubMed ID: 32910434
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Dec 23; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 17. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.
    Zhu B, Edson-Heredia E, Guo J, Maeda-Chubachi T, Shen W, Kimball AB.
    Br J Dermatol; 2014 Nov 23; 171(5):1215-9. PubMed ID: 24749812
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
    Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C.
    Dermatol Ther (Heidelb); 2024 Sep 23; 14(9):2539-2558. PubMed ID: 39153060
    [Abstract] [Full Text] [Related]

  • 20. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004 Sep 23; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.